Literature DB >> 23173947

When should a patient receive an arteriovenous graft rather than a fistula?

Ho-Won Lee, Michael Allon.   

Abstract

There has been a dramatic increase in the placement and use of arteriovenous fistulas (AVF) in US patients with chronic kidney disease over the past few years, in accordance with strong recommendations by Fistula First Initiative and KDOQI guidelines. However, AVF nonmaturation remains a substantial obstacle to achieving functional AVFs in a subset of patients, despite the widespread use of preoperative vascular mapping to assist surgeons in planning access surgery, and the growing use of interventions to salvage nonmaturing AVFs. In the right patient, aggressive efforts result in a functioning AVF, which provides adequate dialysis with relatively few interventions required to maintain its long-term patency for dialysis. In the wrong patient, aggressive efforts to achieve a mature AVF may result in numerous failed surgical and percutaneous procedures and prolonged catheter dependence, with all its associated complications. Thus, strict recommendations to place an AVF in all dialysis patients might not benefit every patient, and may actually harm some patients. There are no randomized clinical trials to address which patients are more suitable for placement of an arteriovenous graft (AVG), rather than an AVF. However, there is a wealth of observational studies, which taken cumulatively, may assist clinicians in identifying those patients who should receive an AVG. In this article, we review the relevant published literature regarding this topic and provide suggestions for stratifying patients who should receive each type of vascular access.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 23173947     DOI: 10.1111/sdi.12040

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  7 in total

1.  Effect of the time to intervention on the outcome of thrombosed dialysis access grafts managed percutaneously.

Authors:  John David Prologo; Gregory Minwell; Jillian Kent; Ali Pirasteh; David Corn
Journal:  Diagn Interv Radiol       Date:  2014 Mar-Apr       Impact factor: 2.630

2.  Immediate-access grafts provide comparable patency to standard grafts, with fewer reinterventions and catheter-related complications.

Authors:  Jason K Wagner; Ellen Dillavou; Uttara Nag; Adham Abou Ali; Sandra Truong; Rabih Chaer; Eric Hager; Theodore Yuo; Michel Makaroun; Efthymios D Avgerinos
Journal:  J Vasc Surg       Date:  2018-10-24       Impact factor: 4.268

Review 3.  Establishing patient-specific criteria for selecting the optimal upper extremity vascular access procedure.

Authors:  Karen Woo; Jesus Ulloa; Michael Allon; Christopher G Carsten; Eric S Chemla; Mitchell L Henry; Thomas S Huber; Jeffrey H Lawson; Charmaine E Lok; Eric K Peden; Larry Scher; Anton Sidawy; Melinda Maggard-Gibbons; David Cull
Journal:  J Vasc Surg       Date:  2017-02-17       Impact factor: 4.268

Review 4.  Patency of ePTFE Arteriovenous Graft Placements in Hemodialysis Patients: Systematic Literature Review and Meta-Analysis.

Authors:  Ronald J Halbert; Gina Nicholson; Robert J Nordyke; Alison Pilgrim; Laura Niklason
Journal:  Kidney360       Date:  2020-10-15

Review 5.  Challenges and novel therapies for vascular access in haemodialysis.

Authors:  Jeffrey H Lawson; Laura E Niklason; Prabir Roy-Chaudhury
Journal:  Nat Rev Nephrol       Date:  2020-08-24       Impact factor: 28.314

6.  Case report of an arteriovenous graft for renal dialysis, with multiple complications treated successfully over 5 years.

Authors:  T Mansoor; D Healy; D Moneley
Journal:  Int J Surg Case Rep       Date:  2019-12-07

7.  Omega-3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease.

Authors:  Ka-Wai Tam; Mei-Yi Wu; Fahad Javaid Siddiqui; Edwin Sy Chan; Yanan Zhu; Tazeen H Jafar
Journal:  Cochrane Database Syst Rev       Date:  2018-11-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.